<p>随着美国市场面临波动的指数和人工智能泡沫的担忧，道琼斯工业平均指数最近创下历史新高后回落，而以纳斯达克为代表的科技股在更广泛的经济不确定性中承受压力。在这个动态环境中，识别高增长科技股需要寻找那些展现出韧性和适应市场变化能力的公司，特别是那些能够有效应对技术进步和投资者情绪的公司。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA 生物制药</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 75 只股票完整列表。</p>
<p>我们将查看筛选工具中一些最佳选择。</p>
<h2>Annexon (ANNX)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Annexon, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发与炎症相关的疾病药物，市值为 7.4081 亿美元。</p>
<p><strong>运营：</strong> Annexon, Inc. 专注于发现和开发针对炎症相关疾病的治疗方案，目前没有收入来源，因为它仍处于临床阶段。</p>
<p>尽管目前尚未盈利，Annexon 正在经历一个变革阶段，获得了大量资本注入和战略研发投资，旨在扭转其财务轨迹。最近通过股权融资筹集了近 7500 万美元，该公司正在增强其资金储备，以支持研究工作和潜在市场扩展。这一战略举措与他们 75.1% 的年收入增长率预期相一致，远远超过美国市场 10.6% 的增长预期。此外，Annexon 对创新的承诺显而易见，他们预计在未来三年内将从亏损转向盈利，这证明了他们在利用尖端技术实现可观增长方面的潜力，尽管面临高度竞争的行业。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Annexon 的动态。</li>
<li>了解 Annexon 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ANNX 收入和支出明细</p>
<h2>Savara (SVRA)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Savara Inc. 是一家临床阶段的生物制药公司，专注于罕见呼吸疾病，市值为 16.7 亿美元。</p>
<p><strong>运营：</strong> Savara Inc. 正在开发针对罕见呼吸疾病的治疗方案，目前没有报告的收入来源。该公司作为一家临床阶段实体，专注于推进其产品管道，而不是产生即时销售收入。</p>
<p>Savara 在近期专利批准和会议展示等一系列活动中展现了在高增长科技领域的韧性。该公司的战略研发投资在其最新的罕见肺病治疗创新中得到了体现，特别是 MOLBREEVI，该药物已获得全球多个卫生机构的多项认证。尽管财务表现面临挑战，净亏损在九个月内扩大至 8660 万美元，Savara 对通过技术推进医疗保健的承诺通过其积极的会议参与和总计约 1.3 亿美元的重大股权融资得到了强调。这种方法不仅为他们的研究提供了资金，还使他们在生物技术领域的未来增长中占据了有利位置，朝着盈利的方向发展。</p>
<ul>
<li>点击这里深入了解 Savara 的完整分析健康报告。</li>
<li>查看我们的历史表现报告，以获取 Savara 过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 SVRA 收入和支出明细</p>
<h2>MNTN (MNTN)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> MNTN, Inc. 运营一个专注于连接电视的绩效营销技术平台，市值为 9.2994 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其互联网软件和服务部门产生收入，总计为 2.7281 亿美元。</p>
<p>MNTN, Inc. 在科技领域展现出强劲的增长，特别是通过战略整合和创新，例如与 Northbeam 的近期合作。这一合作通过将 MNTN 的绩效电视广告活动与 Northbeam 的营销测量平台整合，提升了 MNTN 的广告效果，在其测试阶段显示出 1.8 倍的营销效率比率和 90% 的新网站访问量，表明强劲的表现指标，可能推动未来的增长。此外，MNTN 推出的 QuickFrame AI——一个一体化视频制作平台，突显了其利用尖端技术简化内容创作和分发的承诺，在广告效率和效果上设定了新的标准。通过这些进展，MNTN 不仅在当前趋势中获益，还为在连接电视和数字广告不断演变的领域中保持持续影响力做好了准备。</p>
<ul>
<li>在我们的健康报告中更深入地了解 MNTN 的潜力。</li>
<li>探索历史数据，以跟踪 MNTN 在我们过去部分的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 MNTN 收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>点击开始探索其余 72 只美国高增长科技和人工智能股票。</li>
<li>是这些公司的股东之一吗？确保通过在 Simply Wall St 添加您的投资组合，及时获取重大股票动态的提醒。</li>
<li>使用免费的 Simply Wall St 应用程序更智能地投资，提供全球每个股票市场的详细见解。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人机器人。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

MRKR

ADMA生物制药

PLTR

<p>美国市场正经历波动的指数和对人工智能泡沫的担忧，道琼斯指数在创下历史新高后回落。值得关注的高增长科技股包括 ADMA 生物制药、Marker Therapeutics、Palantir Technologies、Workday、Circle Internet Group、Atlassian、RenovoRx、Zscaler、Duos Technologies Group 和 Procore Technologies。像 Annexon、Savara 和 MNTN 这样的公司因其在科技领域的韧性和战略增长而受到关注。这些公司正在进行重大研发投资和合作，以应对市场变化并推动未来增长</p>

<p>As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, particularly those that can navigate technological advancements and investor sentiment effectively.</p>
<div class="lb-trans"><p>随着美国市场面临波动的指数和人工智能泡沫的担忧，道琼斯工业平均指数最近创下历史新高后回落，而以纳斯达克为代表的科技股在更广泛的经济不确定性中承受压力。在这个动态环境中，识别高增长科技股需要寻找那些展现出韧性和适应市场变化能力的公司，特别是那些能够有效应对技术进步和投资者情绪的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA 生物制药</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 75 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 75 只股票完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中一些最佳选择。</p>
</div><h2>Annexon (ANNX)</h2>
<div class="lb-trans"><h2>Annexon (ANNX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for inflammatory-related diseases, with a market cap of $740.81 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Annexon, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发与炎症相关的疾病药物，市值为 7.4081 亿美元。</p>
</div><p><strong>Operations:</strong> Annexon, Inc. specializes in the discovery and development of treatments for inflammatory-related diseases without current revenue streams, as it remains in the clinical-stage phase.</p>
<div class="lb-trans"><p><strong>运营：</strong> Annexon, Inc. 专注于发现和开发针对炎症相关疾病的治疗方案，目前没有收入来源，因为它仍处于临床阶段。</p>
</div><p>Annexon, despite its current unprofitability, is navigating through a transformative phase with significant capital influx and strategic R&amp;D investments aimed at reversing its financial trajectory. Recently raising nearly $75 million through equity offerings, the company is bolstering its war chest to fuel research endeavors and potential market expansions. This strategic move aligns with their impressive projected annual revenue growth rate of 75.1%, starkly outpacing the broader U.S. market's growth expectation of 10.6%. Furthermore, Annexon's commitment to innovation is evident as they anticipate transitioning from losses to profitability within the next three years—a testament to their potential in harnessing cutting-edge technologies for substantial growth amidst a highly competitive sector.</p>
<div class="lb-trans"><p>尽管目前尚未盈利，Annexon 正在经历一个变革阶段，获得了大量资本注入和战略研发投资，旨在扭转其财务轨迹。最近通过股权融资筹集了近 7500 万美元，该公司正在增强其资金储备，以支持研究工作和潜在市场扩展。这一战略举措与他们 75.1% 的年收入增长率预期相一致，远远超过美国市场 10.6% 的增长预期。此外，Annexon 对创新的承诺显而易见，他们预计在未来三年内将从亏损转向盈利，这证明了他们在利用尖端技术实现可观增长方面的潜力，尽管面临高度竞争的行业。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Annexon.</li>
<li>Learn about Annexon's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Annexon 的动态。</li>
<li>了解 Annexon 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown"/></p>
<p>ANNX Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ANNX 收入和支出明细</p>
</div><h2>Savara (SVRA)</h2>
<div class="lb-trans"><h2>Savara (SVRA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Savara Inc. is a clinical-stage biopharmaceutical company concentrating on rare respiratory diseases, with a market cap of $1.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Savara Inc. 是一家临床阶段的生物制药公司，专注于罕见呼吸疾病，市值为 16.7 亿美元。</p>
</div><p><strong>Operations:</strong> Savara Inc. is engaged in developing therapies for rare respiratory diseases, with no reported revenue streams currently available. The company operates as a clinical-stage entity, focusing on advancing its pipeline rather than generating immediate sales revenue.</p>
<div class="lb-trans"><p><strong>运营：</strong> Savara Inc. 正在开发针对罕见呼吸疾病的治疗方案，目前没有报告的收入来源。该公司作为一家临床阶段实体，专注于推进其产品管道，而不是产生即时销售收入。</p>
</div><p>Savara, amid a flurry of activity including recent patent approvals and conference presentations, exemplifies resilience in the high-growth tech sector. The company's strategic R&amp;D investments are evident with its latest innovations in treatments for rare lung diseases, notably MOLBREEVI which has received multiple designations from health authorities globally. Despite a challenging financial performance with a net loss widening to $86.6 million over nine months, Savara's commitment to advancing healthcare through technology is underscored by an aggressive conference presence and significant equity offerings totaling approximately $130 million. This approach not only fuels their research but also positions them favorably within the biotech landscape for potential future growth as they navigate towards profitability.</p>
<div class="lb-trans"><p>Savara 在近期专利批准和会议展示等一系列活动中展现了在高增长科技领域的韧性。该公司的战略研发投资在其最新的罕见肺病治疗创新中得到了体现，特别是 MOLBREEVI，该药物已获得全球多个卫生机构的多项认证。尽管财务表现面临挑战，净亏损在九个月内扩大至 8660 万美元，Savara 对通过技术推进医疗保健的承诺通过其积极的会议参与和总计约 1.3 亿美元的重大股权融资得到了强调。这种方法不仅为他们的研究提供了资金，还使他们在生物技术领域的未来增长中占据了有利位置，朝着盈利的方向发展。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Savara.</li>
<li>Review our historical performance report to gain insights into Savara's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Savara 的完整分析健康报告。</li>
<li>查看我们的历史表现报告，以获取 Savara 过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>SVRA Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 SVRA 收入和支出明细</p>
</div><h2>MNTN (MNTN)</h2>
<div class="lb-trans"><h2>MNTN (MNTN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> MNTN, Inc. operates a technology platform focused on performance marketing for Connected TV and has a market cap of $929.94 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MNTN, Inc. 运营一个专注于连接电视的绩效营销技术平台，市值为 9.2994 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Internet Software &amp; Services segment, totaling $272.81 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其互联网软件和服务部门产生收入，总计为 2.7281 亿美元。</p>
</div><p>MNTN, Inc. is demonstrating robust growth in the tech sector, particularly through strategic integrations and innovations like its recent partnership with Northbeam. This collaboration enhances MNTN's Performance TV campaigns by integrating them with Northbeam's marketing measurement platform, which during its beta period showed a 1.8x marketing efficiency ratio and 90% new site visits, indicating strong performance metrics that could drive future growth. Additionally, MNTN's introduction of QuickFrame AI—an all-in-one video-production platform—underscores its commitment to leveraging cutting-edge technology to streamline content creation and distribution across various media channels, setting a new standard in advertising efficiency and effectiveness. With these advancements, MNTN is not only capitalizing on current trends but also positioning itself for sustained influence in the evolving landscape of Connected TV and digital advertising.</p>
<div class="lb-trans"><p>MNTN, Inc. 在科技领域展现出强劲的增长，特别是通过战略整合和创新，例如与 Northbeam 的近期合作。这一合作通过将 MNTN 的绩效电视广告活动与 Northbeam 的营销测量平台整合，提升了 MNTN 的广告效果，在其测试阶段显示出 1.8 倍的营销效率比率和 90% 的新网站访问量，表明强劲的表现指标，可能推动未来的增长。此外，MNTN 推出的 QuickFrame AI——一个一体化视频制作平台，突显了其利用尖端技术简化内容创作和分发的承诺，在广告效率和效果上设定了新的标准。通过这些进展，MNTN 不仅在当前趋势中获益，还为在连接电视和数字广告不断演变的领域中保持持续影响力做好了准备。</p>
</div><ul>
<li>Take a closer look at MNTN's potential here in our health report.</li>
<li>Explore historical data to track MNTN's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解 MNTN 的潜力。</li>
<li>探索历史数据，以跟踪 MNTN 在我们过去部分的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth"/></p>
<p>MNTN Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 MNTN 收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Click through to start exploring the rest of the 72 US High Growth Tech and AI Stocks now.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击开始探索其余 72 只美国高增长科技和人工智能股票。</li>
<li>是这些公司的股东之一吗？确保通过在 Simply Wall St 添加您的投资组合，及时获取重大股票动态的提醒。</li>
<li>使用免费的 Simply Wall St 应用程序更智能地投资，提供全球每个股票市场的详细见解。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

3 High Growth Tech Stocks To Watch In The US Market

- 美国市场面临波动的指数和 AI 泡沫担忧，道琼斯工业平均指数创下历史新高后回落。  
- 高增长科技公司如 Annexon 和 Savara 专注于研发，尽管当前无收入，仍展现出强劲的增长潜力。  
- MNTN 通过技术整合和创新，提升广告效率，显示出在数字广告领域的持续影响力。  

美国市场上值得关注的三只高增长科技股票